Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Feb;86(1):33-37.
doi: 10.5935/0004-2749.20230008.

Fecal calprotectin levels in acute anterior uveitis in patients with spondyloarthritis

Caio Cézar Gazim  1 , Angelo Antonio de Borba  1 , Grace Kelly Pelicioni de Castro  2 , Juliana Simioni  3 , Marcelo Luiz Gehlen  2   4 , Odery Ramos Júnior  5 , Thelma Larocca Skare  3
Affiliations

Fecal calprotectin levels in acute anterior uveitis in patients with spondyloarthritis

Caio Cézar Gazim et al. Arq Bras Oftalmol. 2023 Jan-Feb.

Abstract
in English, Portuguese

Purpose: This study measured fecal calprotectin levels in a series of patients with anterior uveitis in order to determine whether anterior uveitis patients with associated spondyloarthritis have higher levels of fecal calprotectin than patients with anterior uveitis of other etiologies. A third group of patients with spondyloarthritis without uveitis was also evaluated to understand the role of acute anterior uveitis in increasing fecal calprotectin.

Methods: In this cross-sectional study, 28 patients were divided into three groups: (a) Group 1, spondyloarthritis and uveitis (n=9); (b) Group 2, spondyloarthritis without uveitis (n=10); and (c) Group 3, uveitis without spondyloarthritis (n=9). The levels of fecal calprotectin were determined.

Results: Groups 1 and 2 showed higher median fecal calprotectin levels (101.0 and 93.0 µg/g, respectively) compared with Group 3 (9.0 µg/g) (p=0.02). However, no relationship between fecal calprotectin levels and the presence of uveitis with spondyloarthritis could be demonstrated.

Conclusion: Patients with spondyloarthritis with or without acute anterior uveitis have significantly elevated levels of fecal calprotectin. This test may be useful for differentiating spondyloarthrit-associated uveitis from uveitis of other etiologies.

Objetivo: Este estudo avaliou os níveis de calprotectina fecal em uma série de pacientes com uveíte anterior na tentativa de determinar se pacientes com uveíte associada com espondiloartrites apresentam níveis mais elevados desta proteína do que pacientes com uveíte anterior de outras etiologias. Um terceiro grupo com espondiloartrites sem uveíte também foi incluído na avaliação para entendimento do papel da uveíte anterior no aumento da calprotectina fecal.

Métodos: Estudo transversal de 28 pacientes divididos em três grupos: (a) com espondiloartrites e uveíte (n=9); (b) com espondiloartrites sem uveíte (n=10) e (c) com uveíte sem espondiloartrites (n=9). A dosagem de calprotectina fecal foi avaliada.

Resultados: Pacientes com uveíte anterior associada a espondiloartrites apresentaram valores medianos maiores de calprotectina fecal (101 µg/g) que os valores dos pacientes com uveíte sem espondiloartrites (9 µg/g), pacientes com espondiloartrites sem uveíte que também demonstraram valores maiores (93.0 µg/g) que os dos pacientes com uveíte sem espondiloartrites (p=0,02).

Conclusão: Pacientes com espondiloartrites com e sem uveíte anterior aguda demonstraram níveis significativamente elevados de calprotectina fecal. Este teste pode ser útil na diferenciação entre uveítes associadas com espondiloartrites de uveítes de outras etiologias. Entretanto, não foi possível demonstrar associação entre o aumento dos níveis de calprotectina fecal e a presença da uveíte em espondiloartrites.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Comparison of fecal calprotectin levels in SpA patients with and without uveitis and in uveitis patients without SpA.
See this image and copyright information in PMC

References

    1. Bañares A, Hernández-García C, Fernández-Gutiérrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am. 1998;24(4):771–784. - PubMed
    1. Skare TL, Silva TQ, Pastro PC. [Uveitis and spondyloarthritis: prevalence and relationship with joint disease] Arq Bras Oftalmol. 2007;70(5):827–830. - PubMed
    1. Zagora SL, Cornish EE, Symes RJ, Younan C, Sammel A, Wakefield D, et al. Inflammatory eye and rheumatic disease. Int J Rheum Dis. 2019;22(12):2091–2095. - PubMed
    1. Pato E, Bañares A, Jover JA, Fernández-Gutiérrez B, Godoy F, Morado C, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol. 2000;27(9):2198–2202. - PubMed
    1. Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem. 2018;87:161–190. - PubMed

Substances

LinkOut - more resources